Lifileucel
Lifileucel
Medication
Lifileucel, sold under the brand name Amtagvi, is a cellular therapy used for the treatment of melanoma.[1][2][3]
The most common adverse reactions include chills, fever, fatigue, tachycardia (abnormally fast heart rate), diarrhea, febrile neutropenia (fever associated with a low level of certain white blood cells), edema (swelling due to buildup of fluid in body tissues), rash, hypotension, hair loss, infection, hypoxia (abnormally low oxygen levels in the body) and feeling short of breath.[3]
Lifileucel is a tumor-derived autologous T cell immunotherapy composed of a recipient's own T cells, a type of cell that helps the immune system fight cancer.[3] A portion of the recipient's tumor tissue is removed during a surgical procedure prior to treatment.[3] The recipient's T cells are separated from the tumor tissue, further manufactured and then returned to the same recipient as a single dose for infusion.[3] It is the first tumor-derived T cell immunotherapy approved by the US Food and Drug Administration (FDA).[3] Lifileucel was approved for medical use in the United States in February 2024.[2][4][5]